{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"42.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"276"}],"units":"Participants"}],"groups":[{"description":"Participants who had disease progression during or following treatment with at least one platinum-containing chemotherapy regimen in the metastatic setting received atezolizumab 1200 mg via IV infusion on Day 1 of 21-day cycles until loss of clinical benefit or unmanageable toxicity.","id":"OG000","title":"Cohort 2: Participants With Second-line or Beyond Treatments"}],"paramType":"NUMBER","populationDescription":"Cohort 2 Safety Evaluable Population. Here, number of participants analyzed = participants for whom ATA samples were available.","reportingStatus":"POSTED","timeFrame":"Day 1 of all cycles (Cycle length = 21 days) and at treatment discontinuation (data cutoff date 04 July 2016, up to maximum length of follow-up of 24.48 months)","title":"Percentage of Participants Positive for Anti-therapeutic Antibodies (ATA) to Atezolizumab","type":"SECONDARY","unitOfMeasure":"percentage of participants"}